iht Obtura: A novel liquid embolic agent with post-embolization radiopacity loss, in endovascular treatment of brain arteriovenous malformations, dural arteriovenous fistulas, and tumors: CLARIDAD trial.
Juan Carlos Llibre-GuerraLeopoldo GuimaraensKrzysztof Bartosz KadziolkaAdnan H SiddiquiRene ChapotAlberto GilPublished in: Journal of neurointerventional surgery (2024)
Obtura was a novel, safe, and effective liquid embolic agent for the treatment of AVMs, DAVFs, and hypervascular tumors. Its key property of significant radiopacity loss contributes to improve anatomical understanding, particularly in staged procedures, as well as reduction in post-procedural imaging artifact. There may be additional benefits of eliminating tantalum from the embolic mixture in terms of lesion penetration.
Keyphrases
- endovascular treatment
- ionic liquid
- high resolution
- clinical trial
- study protocol
- resting state
- white matter
- phase ii
- phase iii
- computed tomography
- functional connectivity
- randomized controlled trial
- multiple sclerosis
- magnetic resonance imaging
- magnetic resonance
- combination therapy
- cerebral ischemia
- photodynamic therapy
- subarachnoid hemorrhage
- brain injury
- dual energy
- fluorescence imaging
- replacement therapy